BeBetter Med Inc. (688759)

Overview

BeBetter Med Inc. is a cutting-edge biotechnology company dedicated to the research and development of innovative pharmaceuticals, with a particular focus on oncology and severe disease treatment. Established in 2012 by a team of scientists with diverse international expertise, the company has successfully developed a varied clinical pipeline that includes both small molecule and RNA-based therapeutics aimed at addressing cancers, autoimmune disorders, and metabolic diseases.

Among its noteworthy advancements are first-in-class compounds such as BEBT-908, a PI3K/HDAC dual inhibitor designed for refractory lymphomas, and BEBT-109, a pan-EGFR inhibitor currently undergoing advanced clinical trials for solid tumors. Furthermore, through its US-based subsidiary, BeBetter Pharma, the company is pioneering next-generation siRNA therapy platforms, which encompass innovative technologies for targeted delivery specifically to renal and hepatic tissues.

BeBetter Med Inc. engages in global collaborations to co-develop, license, and commercialize its therapeutic candidates, all with the intent to meet unmet medical needs while pushing the boundaries of precision medicine. Thanks to its innovative methodologies and strong R&D capabilities, BeBetter has emerged as a significant player in China’s biopharmaceutical sector, making meaningful contributions to the advancement of novel treatments both locally and on the international stage.

Products and Services

• BEBT-908:

  This is a PI3K/HDAC dual inhibitor specifically engineered to treat refractory lymphomas. By targeting two crucial pathways simultaneously, BEBT-908 offers a unique therapeutic strategy designed to overcome resistance commonly seen in lymphoma treatments.

• BEBT-109:

  A pan-EGFR inhibitor currently in advanced clinical trials for solid tumors. BEBT-109 aims to inhibit the epidermal growth factor receptor, which plays a pivotal role in tumor growth and proliferation. Its development is part of a broader strategy to enhance treatment options for patients with various types of solid tumors.

• Next-Generation siRNA Therapy Platforms:

  Through BeBetter Pharma, the company is advancing innovative RNA interference technologies that enable targeted delivery to renal and hepatic tissues. This next-generation platform aims to improve the efficacy and safety profiles of RNA-based therapies, allowing for more precise interventions in diseases affecting these critical organs.

• Collaborative Research and Development:

  BeBetter Med Inc. actively seeks partnerships with other entities for the co-development, licensing, and commercialization of therapeutic candidates. This collaborative approach allows the company to leverage combined expertise and resources to expedite the advancement of its product pipeline while addressing unmet medical needs in diverse therapeutic areas.